Dirk Spitzer

7PUBLICATIONS
23CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 22, 2026
Differential Sensitivity to xCT-inhibition by ME1 expression.

|Jul 18, 2025
Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death.

Kumar S Bishnupuri, Kenneth F Newcomer, Qingqing Gong

|May 02, 2024
Cytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress.

Rony Takchi, Bethany C Prudner, Qingqing Gong

|Apr 14, 2022
Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102.

Caitlyn B Brashears, Bethany C Prudner, Richa Rathore

|Dec 22, 2017
Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.

Lindsay M Kuroki, Xingjian Jin, Igor P Dmitriev

|Jan 19, 2017
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.

Yassar M Hashim, Suwanna Vangveravong, Narendra V Sankpal

Pageof 2

Frequent Collaborators

5 joint publications

Brian A Van Tine

3 joint publications

William G Hawkins

2 joint publications

Caitlyn B Brashears

2 joint publications

Lauren Ross